nach oben

Journal of Cancer Survivorship

Erschienen in:

01.09.2014 | Review

Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research

verfasst von: Julia R. Van Liew, Alan J. Christensen, Janet S. de Moor

Erschienen in: Journal of Cancer Survivorship | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

For patients with hormone receptor positive breast cancer, survivorship entails prolonged self-management of adjuvant treatment in the form of daily hormone therapy. Although sustained daily adherence across the 5-year course of therapy is associated with improved recurrence-free survival outcomes, adherence is suboptimal and many women discontinue hormone therapy prematurely. Factors associated with breast cancer survivors’ nonadherence and nonpersistence are not comprehensively understood. Furthermore, psychosocial variables have only received limited research attention, despite their documented relationships with adherence in other chronic illness populations.

Methods

A systematic literature review identified 14 studies that analyzed relationships between psychosocial factors and breast cancer survivors’ adherence and/or persistence with adjuvant hormone therapy.

Results

Although identified relationships were complex and at times inconsistent, salient conclusions emerged. Interpersonal factors, in the form of positive social support and patient-centered interactions with medical providers, as well as intrapersonal factors, such as anxiety and beliefs about the relative benefits of medication use, were reliably associated with better adherence and persistence. Depression did not demonstrate the negative impact on adherence that has been observed in other medical populations. No relationships between quality of life and adherence were identified.

Conclusions

Adjuvant hormone therapy appears to be a unique context for medication adherence, which warrants further attention and more rigorous analysis in future research.

Implications for Cancer Survivors

Individual patients’ psychosocial characteristics and health care preferences should be considered when striving to optimize medication adherence.

American Cancer Society. Breast cancer facts & figures, 2011-2012. Atlanta: American Cancer Society; 2011.

American Cancer Society. Cancer treatment and survivorship facts & figures 2012-2013. Atlanta: American Cancer Society; 2012.

Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21:28–34.CrossRefPubMed

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.CrossRefPubMed

DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics. CA-Cancer J Clin. 2013. doi:10.3322/caac.21203.

Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington: The National Academies Press; 2005.

Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, et al. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012;1:318–27.PubMedCentralCrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.CrossRef

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.PubMedCentralCrossRefPubMed

10.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010;28:3784–96.CrossRefPubMed

11.

Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Tr. 2006;100:273–84.CrossRef

12.

Cella D, Fallowfield L. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Tr. 2008;107:167–80.CrossRef

13.

Huiart L, Bouhnik A, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48:1939–46.CrossRefPubMed

14.

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. British J Cancer. 2013;108:1515–24.CrossRef

15.

McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. British J Cancer. 2008;99:1763–8.CrossRef

16.

Xu S, Yang Y, Tao W, Song Y, Chen Y, Ren Y, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Tr. 2012;136:495–502.CrossRef

17.

Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–97.PubMed

18.

Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Tr. 2012;134:459–78.CrossRef

19.

Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Tr. 2013;138:325–8.CrossRef

20.

Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the 5-year course. Breast Cancer Res Treat. 2006;99:215–20.CrossRefPubMed

21.

Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen. Cancer. 2007;109:832–9.CrossRefPubMed

22.

Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.CrossRefPubMed

23.

Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322–8.PubMed

24.

Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309–15.CrossRefPubMed

25.

Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23:882–90.CrossRefPubMed

26.

Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Tr. 2012;137:829–36.CrossRef

27.

DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.CrossRefPubMed

28.

DiMatteo RM. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207–18.CrossRefPubMed

29.

Gallant MP. The influence of social support on chronic illness self-management: a review and directions for research. Health Educ Behav. 2003;30:170–95.CrossRefPubMed

30.

Christensen AJ. Patient adherence to medical treatment regimens: bridging the gap between behavioral science and biomedicine. New Haven: Yale University Press; 2004.

31.

Christensen AJ, Howren MB, Hillis SL, Kaboli P, Carter BL, Cvengros JA, et al. Patient and physician beliefs about control over health: symmetrical beliefs predict medication regimen adherence. J Gen Intern Med. 2010;25:397–402.PubMedCentralCrossRefPubMed

32.

Cvengros JA, Christensen AJ, Cunningham C, Hillis SL, Kaboli PJ. Patient preference for and reports of provider behavior: impact of symmetry on patient outcomes. Health Psychol. 2009;28:660–7.CrossRefPubMed

33.

Fann JR, Thomas-Rich A, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiat. 2008;30:112–26.CrossRef

34.

Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol. 2010;29:160–8.CrossRefPubMed

35.

van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg, et al. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer. 2013. doi:10.1007/s00520-013-2041-y.PubMedCentralPubMed

36.

Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt M, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Tr. 2013;138:185–91.CrossRef

37.

Kostev K, Waehlert L, Jockwig A, Jockwig B, Hadji P. Physicians’ influence on breast cancer patient compliance. GMS Ger Med Sci. 2014;12(Doc03):20140120.

38.

Huiart L, Bouhnik A-D, Rey D, Rousseau F, Retornaz F, Meresse M, et al. Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One. 2013;8:e81677.PubMedCentralCrossRefPubMed

39.

Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric. 2013;00:1–8.

40.

Kostev K, May U, Hog D, Eisel J, Kremmers T, Kosteic M, et al. Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany. Int J Clin Pharm Th. 2013;51:969–75.CrossRef

41.

Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97–102.CrossRefPubMed

42.

Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45:431–9.CrossRefPubMed

Titel: Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research
verfasst von: Julia R. Van Liew
Alan J. Christensen
Janet S. de Moor
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 3/2014
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-014-0374-2

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Quality of life and disparities among long-term cervical cancer survivors

Validating the content of a brief informational intervention to empower patients and spouses facing breast cancer: perspectives of both couple members

Predictors of successful use of a web-based healthcare document storage and sharing system for pediatric cancer survivors: Cancer SurvivorLinkTM

Health behaviors among breast, prostate, and colorectal cancer survivors: a US population-based case-control study, with comparisons by cancer type and gender

Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors

Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie